MedTrace Logo

Artemisinin to Reduce The Symptoms of Schizophrenia

NCT00753506 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 66

Last updated 2012-02-28

Study results available
· View outcomes & findings →

Summary

The investigators intend to explore the hypothesis that symptoms of schizophrenia may be reduced by the antimalarial compound artemisinin when used in addition to standard antipsychotic medications.

Conditions

Interventions

DIETARY_SUPPLEMENT

Artemisinin

100 mg of artemisinin twice per day for 10 weeks

DIETARY_SUPPLEMENT

Identical looking placebo capsule

Identical looking placebo twice per day for 10 weeks

Sponsors & Collaborators

  • Stanley Medical Research Institute

    collaborator OTHER

  • Sheppard Pratt Health System

    lead OTHER

Principal Investigators

  • Faith B Dickerson, PhD, MPH · Stanley Research Program at Sheppard Pratt

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-08-31
Primary Completion
2010-05-31
Completion
2010-05-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00753506 on ClinicalTrials.gov